Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
AssigneesMerial Limited, Centre National De La Recherche Scientifique, Institut Gustave Roussy, Universite Paris-Sud
InventorsHervé Poulet, Thierry Heidmann
Life of this patent
Estimating the term…
Abstract
The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
Claims25
A composition comprising:
- a) an expression vector comprising a first polynucleotides encoding an optimized Feline Leukemia Virus (FeLV) envelope (ENV) polypeptide and a second polynucleotide encoding an FeLV GAG/PRO polypeptide;
- and
- b) a pharmaceutically or veterinary acceptable vehicle, diluent or excipient.
An expression vector comprising a first polynucleotide encoding an optimized FeLV ENV polypeptide and a second polynucleotide encoding an FeLV GAG/PRO polypeptide.
A composition comprising:
- a) an expression vector, wherein the vector comprises one or more polynucleotides encoding one or more polypeptides selected from the group consisting of an optimized FeLV polypeptide, a variant or fragment of the optimized FeLV polypeptide, and a mixture thereof;
- and
- b) a pharmaceutically or veterinary acceptable vehicle, diluent or excipient.
An expression vector comprising one or more polynucleotides encoding one or more polypeptides selected from the group consisting of an optimized FeLV polypeptide, a variant or fragment of the optimized FeLV polypeptide, and a mixture thereof.
Dependencies are inferred from the claim text.